BDNF gene therapy (Teika Pharmaceutical/Nippon Medical School)

N/A

Report date: 2025/01/26 17:39:12

Base Information

Drug NameBDNF gene therapy (Teika Pharmaceutical/Nippon Medical School)
Drug Alias Namebrain-derived neurotrophic factor (Teika Pharmaceutical/Nippon Medical School)tyrosine-triple mutated self-complementary adeno-associated virus based gene therapy (Teika Pharmaceutical/Nippon Medical School)
ClassificationBiologics
Mechanisms of ActionBrain-derived neurotrophic factor expression stimulants
TargetsBrain-derived neurotrophic factor
Therapy Area/IndicationsGlaucoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNippon Medical School Foundation
China Registration ClassN/A

Develop Information

Active CompaniesTeika Seiyaku KKNippon Medical School Foundation
Inactive CompaniesN/A
Active IndicationsGlaucoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A